Restoration of left ventricular synchronous contraction after acute myocardial infarction by stem cell therapy: new insights into the therapeutic implication of stem cell therapy for acute myocardial infarction by Chang, S-A et al.
doi:10.1136/hrt.2007.124701 
 2008;94;995-1001; originally published online 1 Nov 2007; Heart
  
Y-B Park, Y-S Choi, H-J Kang and H-S Kim 
S-A Chang, H-K Kim, H-Y Lee, S-Y Choi, B-K Koo, Y-J Kim, D-W Sohn, B-H Oh,
  
 acute myocardial infarction
therapeutic implication of stem cell therapy for 
stem cell therapy: new insights into the
contraction after acute myocardial infarction by 
Restoration of left ventricular synchronous
 http://heart.bmj.com/cgi/content/full/94/8/995




3 online articles that cite this article can be accessed at: 
  
 http://heart.bmj.com/cgi/content/full/94/8/995#BIBL
This article cites 25 articles, 16 of which can be accessed free at: 
Rapid responses
 http://heart.bmj.com/cgi/eletter-submit/94/8/995
You can respond to this article at: 
 service
Email alerting
the top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at
Topic collections
 (9110 articles) Clinical diagnostic tests 
 (1276 articles) Acute coronary syndromes 
 (1470 articles) Echocardiography 
 (9992 articles) Drugs: cardiovascular system 
  
Articles on similar topics can be found in the following collections 
 Notes   
 http://journals.bmj.com/cgi/reprintform
To order reprints of this article go to: 
 http://journals.bmj.com/subscriptions/
 go to: HeartTo subscribe to 
 on 4 September 2009 heart.bmj.comDownloaded from 
Restoration of left ventricular synchronous
contraction after acute myocardial infarction by stem
cell therapy: new insights into the therapeutic
implication of stem cell therapy for acute myocardial
infarction
S-A Chang, H-K Kim, H-Y Lee, S-Y Choi, B-K Koo, Y-J Kim, D-W Sohn, B-H Oh,
Y-B Park, Y-S Choi, H-J Kang, H-S Kim





Stem Cell, Innovative Research




Professor Hyo-Soo Kim, or
Hyun-Jae Kang, Department of
Internal Medicine, Seoul Natioal
University Hospital, 28 Yongon-
dong, Chongno-gu, Seoul, 110–
744, Korea; hyosoo@snu.ac.kr
or nowkang@snu.ac.kr




Objective: To evaluate the effects of stem cell therapy
on restoration of the left ventricular (LV) synchronous
contraction in patients with acute myocardial infarction
(AMI).
Methods: 40 patients with AMI who underwent
successful coronary revascularisation were randomly
allocated to the cell infusion or the control group.
Evaluations were performed with echocardiographic
tissue synchronisation imaging to determine LV dyssyn-
chrony and with cardiac magnetic resonance imaging to
estimate LV ejection fraction (LVEF) at baseline and at
6 months. To quantify the severity of systolic LV
dyssynchrony, the standard deviations of time to peak
systolic velocity of the 12 LV segments (Ts-SD) were
calculated.
Results: At 6 months, greater improvements of Ts-SD
(DTs-SD: 245.0 (40.2) vs 5.0 (39.9) ms, p,0.001) and
LVEF (DLVEF: 6.8% (9.1%) vs 20.2% (6.9%), p = 0.015)
relative to the corresponding baseline values were
observed in the cell infusion group than in the control
group. By multivariate analysis, DTs-SD and baseline LVEF
emerged as the independent determinants of LVEF
improvement and cell infusion, and baseline Ts-SD as the
determinant of DTs-SD improvement. Maximal exercise
capacity measured by symptom-limited treadmill testing
correlated well with Ts-SD but not with LVEF at 6 months
of follow-up.
Conclusion: Stem cell therapy had a favourable effect on
the restoration of LV synchronous contraction in patients
with AMI.
An accumulated body of evidence suggests that
synchronous contraction of the heart is one of the
most important factors in maintaining cardiac
output or stroke volume in concert with adequate
heart rate, preload and afterload.1 Cardiac resyn-
chronisation therapy has been recently developed
and has been shown to guide simultaneous left
ventricular (LV) contraction and consequently to
improve haemodynamic status, exercise perfor-
mance and prognosis in selected patients.2 3
Recently, the beneficial effect of peripheral
blood-derived stem cell treatment on recovery of
the LV systolic performance in myocardial infarc-
tion has been well demonstrated.4–7 Despite the
favourable effect of stem cell therapy on LV
systolic function, no data are available regarding
the role of stem cell therapy in improving LV
synchronous contraction in patients with acute
myocardial infarction (AMI).
Therefore, we sought to evaluate, in this
prospective clinical study using novel echocardio-
graphic tissue synchronisation imaging technique,8
(1) whether stem cell therapy can lead to a re-
coordination of LV systolic contraction and, if so,
(2) whether LV systolic function and exercise




To establish a normal range for the index of LV
synchronicity, we consecutively recruited 129
healthy normal volunteers (86 males, 46 (SD 12;
range 19–69) years). The volunteers had no
previous medical history and had normal physical
and laboratory examinations including electro-
cardiography, echocardiography and either tread-
mill test or coronary computed tomographic
angiography.
We have previously reported a 6-month follow-
up.6 We started the tissue synchronisation imaging
study in the middle of enrolment for MAGIC Cell-
3-DES trial and continued after completion of
enrolment for this trial. In addition to 18 AMI
patients from the MAGIC Cell-3-DES trial, 22
patients who were randomised and treated under
the same protocol were enrolled for this tissue
synchronisation imaging study. Thus, a total of 40
AMI patients were randomised into either the cell
infusion or the control group.
Patients with successful drug-eluting stent (DES)
implantation in the culprit lesion after AMI were
eligible for this study. In addition to the exclusion
criteria of the MAGIC Cell-3-DES trial,6 patients
with atrial fibrillation or with an implanted pace-
maker were also excluded in the current study.
Study protocol
The study was performed using the MAGIC Cell-3-
DES trial protocol and details have been previously
described.6 Briefly, patients were randomly allo-
cated to either the cell infusion or the control
group. Cardiac magnetic resonance imaging (MRI),
transthoracic echocardiography and treadmill
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testing were performed at baseline after DES implantation and
at the 6-month follow-up. For patients assigned to the cell
infusion group, granulocyte-colony-stimulating factor (G-CSF,
Dong-A Pharmaceutical, Seoul, Korea) was administered daily
subcutaneously for a consecutive 3 days at 10 mg/kg body
weight to mobilise stem cells, and then the mobilised stem cells
were collected using a Cobe spectra apheresis system (Cobe
BCT Inc, Lakewood, CO, USA) using the mononuclear cell
collection method. The infusion doses were 1,26109 mono-
cytes per patient, guaranteeing a minimum target cell dose of
76106 CD34+ cells. Stem cells collected were selectively infused
into the coronary artery supplying infarcted myocardium via an
over-the-wire coronary balloon catheter (fig 1).
The study protocol was approved by the institutional review
board of Seoul National University Hospital. Written informed
consent was obtained from all patients after an in-depth
explanation of the procedure and the study risks.
Echocardiographic data acquisition and analysis
Transthoracic echocardiography was conducted using a com-
mercially available device (Vivid 7, GE Medical System, Horten,
Norway) at baseline and 6-month follow-up. After standard
echocardiographic examination, Doppler tissue imaging (DTI)
mode was activated in apical four-chamber, two-chamber and
long-axis views. Great care was taken to get the highest possible
frame rate with sector width and depth optimised. Three
consecutive heart beats were digitally saved in a cineloop format
by two independent echocardiographers for later offline analysis
with a dedicated software package (EchoPac 5.0.1, GE Medical
System). Offline analyses were performed by another echocar-
diographer, who is not involved in image acquisition or patients’
clinical follow-up and who did not know patients’ clinical data.
This tissue synchronisation imaging (TSI) algorithm auto-
matically detects peak positive systolic velocity within a pre-
specified time interval, and displays activation differences in
time to peak positive systolic velocity (Ts) between myocardial
segments through colour-coding directly superimposed on two-
dimensional images, which ranges from green (earliest arrival at
peak systolic velocity), yellow, orange to red (latest arrival at
peak systolic velocity).8 For the measurement of Ts values, the
onset of a QRS signal on the electrocardiogram was used as a
reference point. In TSI mode, we could easily obtain the Ts
values of myocardial segments by simply placing a 6-mm
diameter region of interest in the middle of the segment
concerned. To estimate LV systolic dyssynchrony, we employed
the six-basal and six-mid-segmental model in the LV (total 12
LV segments). After the procurement of the Ts values of 12 LV
myocardial segments, Ts standard deviation (Ts-SD) was
automatically calculated. We adopted Ts-SD of the 12 LV
segments as a surrogate index for LV synchronicity because Ts-
SD obtained using either conventional DTI or TSI tools was
found to be the most reliable index of LV synchronicity9 10—
that is, the greater the value of Ts-SD, the more severe the
systolic dyssynchrony. The average Ts-SD values from three
consecutive heart beats were taken for analysis. In addition, the
global peak systolic myocardial velocity of LV (S9) was
calculated from mean peak systolic velocities from six-basal
segments as a representative marker for the LV inotropic state.
DTs-SD was defined as the Ts-SD at 6-month follow-up minus
Ts-SD at baseline.
Inter-observer and intra-observer variabilities for Ts-SD
measurements were determined by analysing 10 randomly
selected patients by two independent blinded observers. Data
were analysed by least-squares-fit linear regression analysis
using standard-error-of-estimate (SEE).
Cardiac magnetic resonance imaging
Cardiac MRI (Sonata 1.5T, Siemens, Erlangen, Germany) was
performed at baseline and at 6 months. Short axis cine images
with a slice thickness of 8 mm and a gap of 2 mm, were
acquired throughout the entire LV using contiguous two-
dimensional steady state precession sequences. Using ARGUS
software (Siemens, Erlangen, Germany), LV volumes and LV
ejection fraction (LVEF) were calculated by a blinded observer.
Figure 1 Study protocol. MRI, magnetic resonance imaging; TDI, tissue
Doppler imaging; G-CSF, granulocyte-colony-stimulating factor.
Figure 2 Comparisons of changes in left
ventricular ejection fraction (DLVEF) or
Ts-SD changes (DTs-SD) between the
control and cell infusion groups. (A) In the
cell infusion group, LVEF improvements
were significantly greater than in the
control group. (B) The cell infusion group
showed a remarkable reduction in DTs-
SD compared to the control group,
indicating a better improvement in left
ventricular synchronous contraction in the
cell infusion group.
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DLVEF was defined as LVEF at 6-month follow-up minus LVEF
at baseline.
Treadmill exercise test
Patients underwent a maximum symptom-limited treadmill
testing using the modified Bruce protocol at 1 week and
6 months after revascularisation. All anti-anginal medication
was continued. The end points of this test included angina
pectoris, fatigue, dyspnoea and a significant decrease in blood
pressure of more than 10 mm Hg. The achievement of a
maximal age-related heart rate was not a reason for termina-
tion. Exercise capacity was measured using metabolic equiva-
lents (METs), an estimate based on treadmill speed and grade.
Statistical analysis
All values are expressed as means (SD) or as percentages. To
compare parametric variables at baseline and at 6-month
follow-up, we used the paired t test or Wilcoxon signed rank
sum test as appropriate. Comparisons of the continuous
variables between the cell infusion and control groups were
performed using the independent t test, whereas Fisher’s exact
test was used for categorical variables. Pearson’s correlation
analysis was employed to compare the relation between DTs-
SD and DLVEF after the 6-month follow-up and the relation
between Ts-SD and exercise duration at the 6-month follow-up.
Multivariate backward stepwise logistic regression analyses
were undertaken to identify independent determinants of
DLVEF and DTs-SD. All statistical analyses were performed
with SPSS 12.0 (SPSS Inc, Chicago, IL, USA), and p values of
,0.05 were taken to indicate statistical significance.
RESULTS
Study population
Mean Ts-SD obtained from 129 normal subjects was 23.9 (11.2)
ms and, hence, a Ts-SD of 46 ms (mean (+2 SD) for normal
subjects) was chosen as a cut-off upper limit value to define LV
synchronous contraction. Since no significant change in Ts-SD
was detected with ageing (p = 0.75), no further correction for
age was carried out in the following analyses.
All the patients underwent the apheresis process without
immediate complication and were successfully given stem cell
infusion, which contains 9.04 (8.04)6107 CD34+ cells and
completed the follow-up at 6 months. Among them, 35
performed the exercise test, the other five complained of leg
pain caused by degenerative arthritis or claudication. Baseline
clinical, echocardiographic and cardiac MRI data of the patient
cohort are summarised in table 1.
There was a wide range of variation in Ts-SD and LVEF at
baseline in both the control and the cell infusion groups, but
there were no significant differences between the two groups in
terms of baseline characteristics. When a Ts-SD of .46 ms was
used to define significant systolic asynchrony, it was found to
be present in 15 patients (75%) in the control group and in 17
patients (85%) in the cell infusion group (p = 0.70), indicative of
the presence of LV dyssynchrony in a large proportion of the
patients. Again, baseline characteristics were similar between
patients with (responders) and those without (non-responders)
an improvement in LV dyssynchrony except for the presence of
a higher proportion of patients with cell infusion treatment in
the responders group (table 1).
Improvement of Ts-SD and LV systolic function by stem cell
therapy
At the 6-month follow-up, LVEF increment from baseline was
significantly higher in the cell infusion group, compared to the
control group (DLVEF: 6.8% (9.1%) vs 0.2% (6.9%), p = 0.015)
(fig 2). Ts-SD values were markedly improved at the 6-month
follow-up than at baseline in the cell infusion group (108.0
(50.1) ms vs 63.0 (54.9) ms, p,0.001), but not in the control
group (98.2 (52.8) ms vs 103.2 (50.1) ms, p = 0.59) (table 2),
implying that DTs-SD improvement was greater in the cell
infusion group than in the control group (245.0 (40.2) ms vs 5.0
(39.9) ms, p,0.001) (fig 2). DTs-SD exhibited a significant
correlation with DLVEF in the entire population (r = 20.43,
p = 0.005) (fig 3). Changes in S9 were comparable between the
two groups (20.35 (1.31) cm/s in the cell infusion group vs
20.20 (0.89) cm/s in the control group, p = 0.13), indicating no
significant difference between the two groups in terms of the
alteration in LV contractility.
Inter-observer and intra-observer variability of Ts-SD mea-
surements showed excellent agreements (inter-observer correla-
tion: r = 0.97, SEE = 12.3, p,0.001 and intra-observer
correlation: r = 0.99, SEE = 8.1, p,0.001).
Determinants of LV systolic function and LV synchronicity
improvements
To elucidate independent determinants of LVEF improvement,
we performed multivariate analysis and included age, gender,
the group factor (control vs cell infusion), medications used,
hypertension, diabetes, changes of infarct volume, baseline
LVEF, baseline LV end-systolic volume, baseline Ts-SD, baseline
QRS duration, DS9 and DTs-SD as independent variables (no
change (DLVEF ,5%) or an aggravation of LVEF were coded as
0 and an LVEF improvement (DLVEF >5%) as 1). DTs-SD and
baseline LVEF were emerging variables identified as independent
determinants for LVEF improvement (table 3).
To identify determinants of LV dyssynchrony improvement,
we again performed multivariate analysis. The dependent
variable was DTs-SD (no change or aggravation of Ts-SD
(DTs-SD >0) was coded as 0 and Ts-SD improvement (DTs-SD
,0) as 1). Independent variables were age, gender, the group
factor, medications used, hypertension, diabetes, changes of
infarct volume, baseline LVEF, baseline LV end-systolic volume,
baseline Ts-SD, baseline QRS duration, DS9 and DLVEF. The
determinants of DTs-SD improvement were baseline Ts-SD and
Figure 3 Scatter plots for correlations between changes in left
ventricular ejection fraction (DLVEF) and Ts-SD changes (DTs-SD) after
6-month follow-up in all patients, in the control and in the cell infusion
groups. Significant negative correlations were noted for all patients and
for the cell infusion and control group, respectively.
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the group factor—that is, the performance of cell therapy
(table 3).
Correlation between LV synchronicity and exercise capacity
Maximal exercise capacity in the control group did not improve
significantly at the 6-month follow-up, whereas exercise
capacity showed a significant improvement in the cell infusion
group (table 2).
We also found that exercise capacity at the 6-month follow-
up was significantly correlated with Ts-SD (r = 20.54,
p = 0.001) but not with LVEF (p = 0.46, fig 4). In the cell
infusion group, Ts-SD was also found to be strongly correlated
with maximum exercise capacity (r = 20.61, p = 0.007). But,
LVEF failed to show a significant correlation with maximum
exercise capacity (p = 0.59).
There were no deaths, new MI, hospitalisation due to angina
or heart failure or revascularisation during 6-month follow-up in
either groups.
DISCUSSION
This study, for the first time, demonstrates that stem cell
therapy improved LV dyssynchrony in systole after AMI, as
Table 1 Baseline clinical, echocardiographic, and cardiac magnetic resonance imaging (MRI) data according to either the presence or absence of cell
infusion therapy or the response of Ts-SD after 6-month follow-up
Subjects Control Cell infusion p Value Responders* Non-responders* p Value
Number 20 20 24 16
Age (years) 57.1 (11.9) 56.6 (13.1) 0.90 56.1 (13.0) 57.9 (11.7) 0.66
Male, n (%) 16 (80) 17 (85) 1.0 20 (83) 13 (81) 1.0
Hypertension, n (%) 7 (35) 12 (60) 0.11 13 (54) 6 (38) 0.30
Diabetes, n (%) 7 (35) 5 (25) 0.49 7 (30) 5 (31) 0.89
QRS duration (ms) 93.0 (17.2) 96.5 (22.3) 0.58 93.8 (21.6) 96.3 (17.1) 0.70
Primary reperfusion, n (%) 13 (65) 10 (50) 0.34 15 (62) 8 (50) 0.43
Extent (1-vessel: 2-vessel, 3-vessel
disease)
11:9 11:9 1.0 13:11 9:7 0.90
Infarct related artery (LAD:LCX:RCA) 8:2:10 13:3:4 0.14 15:2:7 6:3:7 0.28
Cardiac MRI parameters
LVESV (ml){ 65.5 (36.5) 64.7 (22.0) 0.93 62.9 (22.0) 68.5 (39.2) 0.56
LV EDV (ml){ 134.6 (32.6) 134.7 (32.4) 0.99 131.5 (30.7) 139.3 (34.5) 0.46
LV EF (%){ 53.2 (15.7) 52.6 (9.1) 0.89 52.7 (11.0) 53.3 (15.2) 0.70
Infarct volume (ml){ 25.3 (15.5) 31.7 (20.3) 0.28 28.1 (16.9) 28.9 (20.1) 0.89
Doppler parameters
E (m/s) 0.74 (0.21) 0.67 (0.16) 0.22 0.72 (0.18) 0.68 (0.20) 0.54
A (m/s) 0.71 (0.19) 0.64 (0.20) 0.30 0.66 (0.18) 0.70 (0.21) 0.62
E/A ratio 1.12 (0.49) 1.11 (0.41) 0.94 1.15 (0.40) 1.08 (0.54) 0.64
DT (ms) 194.28 (53.01) 180.85 (36.24) 0.36 177.87 (41.63) 202.63 (47.7) 0.10
S9 (cm/s) 5.45 (1.89) 5.26 (1.40) 0.72 5.47 (1.47) 5.19 (1.92) 0.61
Ts-SD 98.20 (52.83) 108.00 (50.11) 0.55 113.50 (47.25) 87.50 (54.08) 0.12
Ts-SD .46 ms, n (%) 15 (75%) 17 (85%) 0.70 21 (88%) 11 (68.8%) 0.23
Cell infusion, n (%) 0 (0%) 20 (100%) ,0.001 17 (71%) 3 (19%) 0.003
Medications used, n (%)
b-blockers 14 (70%) 17 (85%) 0.45 18 (75%) 13 (81%) 0.72
ACEIs or ARBs 18 (90%) 19 (95%) 1.0 23 (96%) 14 (88%) 0.55
Aspirin or clopidogrel 20 (100%) 20 (100%) 1.0 24 (100%) 16 (100%) 1.0
Statins 18 (90%) 16 (80%) 0.66 20 (83%) 14 (88%) 1.0
LV, left ventricular; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; DT, deceleration time of E wave; S9, mean peak systolic myocardial velocity; Ts-SD,
standard deviation of the time to peak myocardial velocities; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
*Responders were defined as patients with (Ts-SD at 6 months 2 Ts-SD at baseline (DTs-SD)) ,0 and non-responders as those with DTs-SD >0.
{Measured by cardiac magnetic resonance imaging.




Cell infusion Cell infusion
p ValueBaseline Follow-up Baseline Follow-up
LV EF (%)* 53.2 (15.7) 53.4 (12.6) 0.88 52.6 (9.1) 59.4 (10.6) 0.004
LV ESV (ml)* 65.5 (36.5) 69.8 (37.3) 0.20 64.7 (22.0) 61.6 (31.7) 0.56
LV EDV (ml)* 134.6 (32.6) 142.4 (38.5) 0.12 134.7 (32.4) 145.0 (38.0) 0.12
LV stroke volume (ml)* 69.0 (13.6) 72.5 (12.2) 0.24 70.0 (17.6) 83.3 (15.6) 0.005
Infarct volume (ml)* 25.3 (15.5) 21.9 (9.9) 0.079 31.4 (20.8) 23.6 (16.5) 0.008
Ts-SD 98.2 (52.8) 103.2 (50.1) 0.59 108.0 (50.1) 63.0 (54.9) ,0.001
S9 (cm/s) 5.5 (1.9) 5.1 (1.4) 0.25 5.26 (1.40) 5.5 (1.2) 0.70
QRS duration (ms) 93.0 (17.2) 93.0 (13.4) 1.0 96.5 (22.3) 98.5 (20.3) 0.32
Maximal exercise capacity (METs) 9.3 (2.8) 9.8 (3.5) 0.35 8.8 (2.8) 10.1 (2.4) 0.002
*Measured by cardiac magnetic resonance imaging.
LV, left ventricular; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; Ts-SD, standard deviation of the time to peak myocardial velocities; S9, mean peak
systolic myocardial velocity.
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evidenced by a significant reduction in Ts-SD (fig 5). Moreover,
Ts-SD was found to be correlated with exercise capacity
6 months after stem cell therapy, suggesting that a restoration
of LV dyssynchrony is related to an improved exercise capacity.
LV dyssynchrony and its assessment with tissue synchronisation
imaging
The presence of LV dyssynchrony poses a higher risk of
functional worsening and an important predictor of poor
outcome independent of LVEF and other clinical factors.11 12
Thus, the correction of LV dyssynchrony may be translated to a
favourable prognosis13 14 and the identification of LV mechanical
dyssynchrony is of crucial importance.
Echocardiography has been the cornerstone for serial
assessment of systolic dyssynchrony. Most of all, DTI has
been the most widely used method with its high temporal
resolution, high reproducibility and its ability to define
regional timing and contractility. TSI is a novel echocardio-
graphic imaging tool derived from DTI velocity data images.
Previous studies have demonstrated the usefulness of TSI
technique in assessing LV dyssynchrony.8 10 15 Among the
parameters frequently used to assess LV dyssynchrony, Ts-SD
is an reliable and powerful index that embraces the informa-
tion of all the 12 LV segments, and thus Ts-SD seems to be a
more useful surrogate for LV dyssynchrony in patients with
ischaemic cardiomyopathy. This concept was evidently
supported by the earlier study by Yu et al, where Ts-SD is
the single reliable index for LV dyssynchrony in ischaemic
cardiomyopathy.10
Restoration of LV synchronous contraction—a plausible
mechanism of LVEF improvement with stem cell therapy
Stem cell therapy was reported to be effective in numerous
clinical trials with diverse stem cell collection and delivery
protocol.6 16–18 Schachinger et al reported improved LV systolic
function in their randomised double-blind trial using intracor-
onary infusion of bone marrow-derived progenitor cells4 and
Ince et al reported favourable results using peripheral stem cells
by a mobilisation method with G-CSF.7 Most of them reported
the improvement of LV systolic performance as shown by LVEF
improvement and the mechanism of this phenomenon has been
under discussion.
Although angiogenesis and myocardial regeneration have
been suggested to account for improved cardiac systolic
function by stem cell therapy,19 arguments were raised because
only small numbers of stem cells could be observed in the long-
term follow-up animal studies. Thus, direct myogenesis and
angiogenesis were regarded as insufficient in explaining the
functional improvements associated with stem cell therapy.20 In
these respects, the paracrine effects of transplanted stem cells
were newly proposed as a reason for the improvements observed
in clinical and preclinical studies,21 though this is mainly
supported by circumstantial evidence. Additionally we do not
have adequate methodology to evaluate myocardial regenera-
tion and angiogenesis in a clinical setting. Only surrogate
markers such as changes in infarct volume, myocardial
perfusion score and global peak systolic myocardial velocity
were used to evaluate the underlying mechanism of stem cell
therapy. In fact, the underlying mechanism of this has not been
clearly elucidated till now.
In the present study, we proposed changes of LV synchrony
as a novel clinical parameter to explain the mechanism of stem
cell therapy. We clearly demonstrated improvement of LV
Table 3 Determinants for the improvement of the left ventricular ejection fraction or synchronicity









statistics p Value 95% CI
Age 0.961 1.425 0.233 0.899 to 1.026 Age 1.025 1.512 0.219 0.985 to 1.067
Gender 1.029 ,0.001 0.988 0.022 to 47.496 Gender 5.124 1.737 0.188 0.451 to 58.189
DM 2.693 0.877 0.349 0.339 to 21.408 DM 1.365 0.103 0.748 0.205 to 9.091
HT 0.666 0.146 0.702 0.0830 to 5.342 HT 1.263 0.055 0.814 0.181 to 8.832
ACEI or ARB 7.128 3.221 0.073 0.834 to 60.888 ACEI or ARB 0.689 0.057 0.811 0.032 to 14.745
b-blocker 0.124 3.346 0.067 0.013 to 1.161 b-blocker 1.342 0.054 0.817 0.111 to 16.167
QRS duration 1.023 0.820 0.365 0.970 to 1.088 QRS duration 0.991 0.136 0.712 0.945 to 1.039
LV EF (baseline) 1.012 0.041 0.840 0.903 to 1.134 LV EF (baseline) 0.977 5.912 0.015 0.959 to 0.996
LV ESV (baseline) 0.978 1.273 0.259 0.940 to 1.017 LV ESV (baseline) 0.990 0.795 0.373 0.968 to 1.012
Ts-SD (baseline) 1.019 4.595 0.032 1.002 to 1.037 Ts-SD (baseline) 0.998 0.039 0.843 0.975 to 1.021
D infarct volume 1.041 0.536 0.464 0.935 to 1.159 D infarct volume 0.929 2.998 0.083 0.854 to 1.010
D LV EF 1.094 1.353 0.245 0.940 to 1.273 D Ts-SD 0.982 3.930 0.047 0.965 to 0.999
D S9 1.199 0.148 0.701 0.476 to 3.019 D S9 1.458 0.479 0.489 0.501 to 4.238
Group factor (control vs
infusion)
0.052 9.341 0.002 0.008 to 0.346 Group factor (control vs
infusion)
0.428 0.927 0.336 0.076 to 2.410
DM, diabetes mellitus; HT, hypertension; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; LV, left ventricular; EF, ejection fraction; ESV, end-
systolic volume; S9, mean peak systolic myocardial velocity; Ts-SD, standard deviation of the time to peak myocardial velocities.
Figure 4 Correlation between the degree of LV dyssynchrony and
exercise capacity at 6-month follow-up. Ts-SD measured 6 months after
cell infusion showed a good correlation with maximum exercise capacity
in all study subjects (r = 20.54, p = 0.001).
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synchrony after stem cell therapy as well as the close association
between this improvement and LVEF enhancement. Of note, on
multivariate analysis, LVEF improvement by stem cell therapy
is independently related to a re-coordination of LV contraction
as well as baseline LVEF rather than with to augmented
contractility of the LV myocardium evaluated by S9. Although
reductions in infarct volume were more prominent in the cell
infusion group, infarct size did not play a vital part in altering
the LVEF determinant or LV dyssynchrony, as demonstrated by
multivariate analysis.
In hearts with asynchronous contraction, myocardial seg-
ments contracting earlier might add an additional burden to
late-contracting myocardial segments beyond the preload
naturally provided and, thus, cause substantial energy wastage
during their contraction to overcome the increased preload,
which could influence the contractility of late-contracting
myocardium in view of the classic Frank-Starling mechanism
locally operated.2 22 Moreover, asynchronous LV activation was
shown to be associated with changes in regional myocardial
blood flow and regional metabolism.23 Based on these previous
observations, we can easily understand that asynchronous LV
contraction could have a deleterious impact on the progression
of underlying LV dysfunction, irrespective of its aetiology and
consequently patients’ prognosis. The alleviation of abnormally
increased myocardial preload may have favourable repercussions
on the recovery of regional myocardial function, which would
in turn lead to LV reverse remodelling23 and LV systolic
functional improvement. Accordingly, stem cell therapy,
through LV resynchronisation, is likely to be a clinically
relevant adjunctive therapy that enhances outcomes of patients
with MI and LV dyssynchrony beyond that acquired by
revascularisation.
Restoration of LV dyssynchrony and exercise capacity
Restoration of LV synchronicity with biventricular pacing
improved symptoms and the functional capacities of patients
with heart failure.24 In this study, the exercise capacity of
patients in the cell infusion group improved at the 6-month
follow-up, and Ts-SD, a surrogate index of LV synchronicity,
but not LVEF, displayed a good correlation with maximal
exercise capacity 6 months after stem cell therapy. This
phenomenon suggests that the restoration of LV synchrony
obtained by stem cell therapy is largely responsible for
functional improvements in patients treated by stem cell
therapy.
Study limitations
We cannot provide prognostic data owing to the relatively short
follow-up period. However, earlier reports have suggested that
restoring LV mechanical synchronicity mitigates patients’
morbidity and mortality.13 25 Long-term follow-up results to
show that the restored LV dyssynchrony after stem cell therapy
led to a better prognosis are expected to be available in the near
future. In addition, efforts to identify baseline clinical or
echocardiographic parameters predictive of LV synchrony
improvements after stem cell therapy are probably worthwhile,
although the present study failed in this respect.
CONCLUSIONS
Treatment with peripheral blood stem cells mobilised by G-CSF
offers a unique opportunity to restore LV synchronous
contraction, which may be one of the underlying mechanisms
for the improvement in LVEF and exercise capacity by stem cell
therapy in patients with AMI. The hypothesis that the
Figure 5 A representative example of tissue synchronisation imaging in the apical four-chamber, two-chamber and three-chamber views in a patient
with AMI, who was assigned to the cell infusion group. Upper panel (A) represents images obtained at baseline. Red colours, indicating myocardial
segments contracting in a dyssynchronous fashion, were superimposed on mid-anterolateral, anterior and apical walls. After 6 months of follow-up, the
extent of the red coloured areas was remarkably diminished, as shown in lower panel (B), indicative of a significant improvement in left ventricular
synchronicity with stem cell therapy.
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restoration of LV synchronicity after stem cell therapy may
improve patients’ long-term survival need to be clarified in
future studies.
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